| Nome |
# |
|
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: Evidence for a NOTCH1 mutation-driven epigenetic dysregulation, file e2913fdb-7633-f688-e053-3705fe0a67e0
|
346
|
|
Mutations in the 3' untranslated region (3' UTR) of NOTCH1 are associated with low CD20 expression levels in chronic lymphocytic leukemia, file e2913fdb-d4ea-f688-e053-3705fe0a67e0
|
154
|
|
Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies, file e2913fdb-743a-f688-e053-3705fe0a67e0
|
128
|
|
Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications, file e2913fdc-3c3e-f688-e053-3705fe0a67e0
|
122
|
|
Invasive meningococcal disease in three siblings with hereditary deficiency of the 8th component of complement: Evidence for the importance of an early diagnosis, file e2913fdb-0cad-f688-e053-3705fe0a67e0
|
119
|
|
Meniscal ossicles as micro-CT imaging biomarker in a rodent model of antigen-induced arthritis: A synchrotron-based x-ray pilot study, file e2913fdb-9c71-f688-e053-3705fe0a67e0
|
113
|
|
Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers, file e2913fda-ecb2-f688-e053-3705fe0a67e0
|
112
|
|
Complement as a biological tool to control tumor growth, file e2913fdc-9578-f688-e053-3705fe0a67e0
|
85
|
|
The terminal complement pathway is activated in septic but not in aseptic shoulder revision arthroplasties, file e2913fdd-abf4-f688-e053-3705fe0a67e0
|
61
|
|
High fecal calprotectin levels are associated with SARS-CoV-2 intestinal shedding in COVID-19 patients: A proof-of-concept study, file e2913fde-7364-f688-e053-3705fe0a67e0
|
49
|
|
Mutations in the 3' untranslated region (3' UTR) of NOTCH1 are associated with low CD20 expression levels in chronic lymphocytic leukemia, file e2913fdb-d3a5-f688-e053-3705fe0a67e0
|
48
|
|
New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats, file e2913fdd-fa58-f688-e053-3705fe0a67e0
|
42
|
|
Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice., file e2913fdf-3514-f688-e053-3705fe0a67e0
|
42
|
|
Nanoparticles-based oligonucleotides delivery in cancer: Role of zebrafish as animal model, file e2913fdf-59a0-f688-e053-3705fe0a67e0
|
36
|
|
Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis, file e2913fdd-7c6a-f688-e053-3705fe0a67e0
|
33
|
|
Targeted delivery of neutralizing anti-C5 antibody to renal endothelium prevents complement- dependent tissue damage, file e2913fdb-a598-f688-e053-3705fe0a67e0
|
28
|
|
Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination, file e2913fdf-9d71-f688-e053-3705fe0a67e0
|
27
|
|
Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients, file e2913fde-cd14-f688-e053-3705fe0a67e0
|
25
|
|
The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target, file e2913fdd-9925-f688-e053-3705fe0a67e0
|
18
|
|
The Inflammatory Feed-Forward Loop Triggered by the Complement Component C3 as a Potential Target in Endometriosis, file e2913fde-8635-f688-e053-3705fe0a67e0
|
14
|
|
High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids, file e2913fde-f907-f688-e053-3705fe0a67e0
|
10
|
|
Hereditary deficiency of the second component of complement: Early diagnosis and 21-year follow-up of a family, file e2913fdd-a34d-f688-e053-3705fe0a67e0
|
9
|
|
Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies, file bcf1eb41-7790-4913-b621-0b596eea8488
|
8
|
|
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy, file e2913fda-2637-f688-e053-3705fe0a67e0
|
8
|
|
Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice., file e2913fda-2f92-f688-e053-3705fe0a67e0
|
8
|
|
The J-elongated conformation of b2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome, file e2913fde-32d3-f688-e053-3705fe0a67e0
|
8
|
|
Plasminogen activator-coated nanobubbles targeting cell-bound β2-glycoprotein I as a novel thrombus-specific thrombolytic strategy, file 8ba9d48b-2300-48eb-aeaf-6e8300ff608f
|
7
|
|
Critical role and therapeutic control of the lectin pathway of complement activation in an abortion-prone mouse mating, file e2913fda-3e48-f688-e053-3705fe0a67e0
|
7
|
|
Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice., file e2913fda-fb40-f688-e053-3705fe0a67e0
|
7
|
|
Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery, file e2913fde-d6c6-f688-e053-3705fe0a67e0
|
7
|
|
Targeted delivery of neutralizing anti-C5 antibody to renal endothelium prevents complement- dependent tissue damage, file e2913fdb-a6b9-f688-e053-3705fe0a67e0
|
6
|
|
Critical role and therapeutic control of the lectin pathway of complement activation in an abortion-prone mouse mating, file e2913fdf-0108-f688-e053-3705fe0a67e0
|
5
|
|
An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies., file e2913fd9-0018-f688-e053-3705fe0a67e0
|
4
|
|
Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery, file e2913fda-3eef-f688-e053-3705fe0a67e0
|
4
|
|
Cubosomes for in vivo fluorescence lifetime imaging, file e2913fdb-747e-f688-e053-3705fe0a67e0
|
4
|
|
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: Evidence for a NOTCH1 mutation-driven epigenetic dysregulation, file e2913fdb-8105-f688-e053-3705fe0a67e0
|
4
|
|
Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis, file e2913fdc-f6f5-f688-e053-3705fe0a67e0
|
4
|
|
High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids, file e2913fdd-5334-f688-e053-3705fe0a67e0
|
4
|
|
Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination, file e2913fdf-5d85-f688-e053-3705fe0a67e0
|
4
|
|
Biological Features of Nanoparticles: Protein Corona Formation and Interaction with the Immune System, file 68b39a18-40bd-4075-8975-43585e619686
|
3
|
|
null, file e2913fd9-0b05-f688-e053-3705fe0a67e0
|
3
|
|
OP0023 Targeted Polymeric Nanoparticles as Diagnostic and Therapeutic Tool for Rheumatoid Arthritis, file e2913fdb-a6c3-f688-e053-3705fe0a67e0
|
3
|
|
The terminal complement pathway is activated in septic but not in aseptic shoulder revision arthroplasties, file e2913fdd-b031-f688-e053-3705fe0a67e0
|
3
|
|
Complement Activation and Thrombin Generation by MBL Bound to β2-Glycoprotein I, file e2913fde-7559-f688-e053-3705fe0a67e0
|
3
|
|
The Inflammatory Feed-Forward Loop Triggered by the Complement Component C3 as a Potential Target in Endometriosis, file e2913fde-8634-f688-e053-3705fe0a67e0
|
3
|
|
Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5., file e2913fd9-021c-f688-e053-3705fe0a67e0
|
2
|
|
New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles., file e2913fd9-16ee-f688-e053-3705fe0a67e0
|
2
|
|
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia, file e2913fdb-2c5b-f688-e053-3705fe0a67e0
|
2
|
|
Targeted delivery of neutralizing anti-C5 antibody to renal endothelium prevents complement- dependent tissue damage, file e2913fdb-a5a8-f688-e053-3705fe0a67e0
|
2
|
|
Targeted delivery of neutralizing anti-C5 antibody to renal endothelium prevents complement- dependent tissue damage, file e2913fdb-a6b7-f688-e053-3705fe0a67e0
|
2
|
|
Diagnostic and prognostic role of eEF1A in chronic lymphocytic leukaemia, file e2913fdc-f2e8-f688-e053-3705fe0a67e0
|
2
|
|
Effects of eEF1A1 targeting by aptamer/siRNA in chronic lymphocytic leukaemia cells, file e2913fdd-2504-f688-e053-3705fe0a67e0
|
2
|
|
Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab, file e2913fdd-3bfd-f688-e053-3705fe0a67e0
|
2
|
|
An allosteric redox switch in domain V of β2-glycoprotein I controls membrane binding and anti-domain I autoantibody recognition, file e2913fde-7558-f688-e053-3705fe0a67e0
|
2
|
|
Cubosomes stabilized by a polyphosphoester-analog of Pluronic F127 with reduced cytotoxicity, file e2913fde-7faf-f688-e053-3705fe0a67e0
|
2
|
|
Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma., file e2913fd8-fb8f-f688-e053-3705fe0a67e0
|
1
|
|
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab., file e2913fd8-fc28-f688-e053-3705fe0a67e0
|
1
|
|
null, file e2913fd9-183b-f688-e053-3705fe0a67e0
|
1
|
|
A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles, file e2913fda-3e90-f688-e053-3705fe0a67e0
|
1
|
|
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia, file e2913fdb-2ad4-f688-e053-3705fe0a67e0
|
1
|
|
Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis, file e2913fdc-f6f6-f688-e053-3705fe0a67e0
|
1
|
|
Complement system and phagocytosis in a colonial protochordate, file e2913fdd-3cb7-f688-e053-3705fe0a67e0
|
1
|
| Totale |
1765 |